NCT07453888: An ongoing trial by Dompé Farmaceutici S.p.A
This trial is ongoing. It must report results 1 year, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07453888 |
|---|---|
| Title | Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 1, 2026 |
| Completion date | Sept. 30, 2027 |
| Required reporting date | Sept. 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 3, 2026 |
| Days late | None |